Xintela publishes interim report for the third quarter

Summary of the interim report The “company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2019-30 Sep 2019)· Income amounted to TSEK 3 (1,012).· Loss before tax totalled TSEK -28,081 (-17,581).· Loss per share* was SEK -0.71 (-0.58).· At 30 September 2019, the equity/assets […]

Year-end Report 2018

The aim is set for clinical studies The final quarter of the year was very eventful, and successful in terms of both projects and financing. We conducted a directed share issue of MSEK 50 to the German orthopaedic company Bauerfeind AG. In the companies stem-cell project, our aim is to commence clinical trials in Australia. […]

XINTELA TO SPIN OUT ONCOLOGY BUSINESS

Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that the company has made the decision to spin out its oncology business to a newly formed subsidiary company, Targinta AB. The Xintela Board has decided to move the oncology business into a separate company, with plans to distribute shares to Xintela’s owners and […]

Xintela signs Letter of Intent with CO.DON

Xintela AB (publ) announces today that the company has signed a Letter of Intent with the leading European cell therapy company CO.DON. The parties intend to co-develop a stem cell product for the treatment of osteoarthritis, based on Xintela’s stem cell technology. CO.DON will pay an exclusivity fee for a 6- month period, during which […]

Xintela receives MUMS-status for the treatment of osteoarthritis in horses

Lund, Sweden, 28th of June 2018 – Xintela announces today that the company has received MUMS-status (Minor Use Minor Species) in Europe for the treatment of degenerative joint disease, including osteoarthritis, in horses. MUMS-status is the veterinary equivalent of Orphan Drug in human medicine. The MUMS classification gives a significant reduction of documentation requirements prior […]

Xintela prepares for oncology spinout

Xintela AB (publ) announces today that the company has decided to prepare for a possible spin-out of its oncology business into a separate company to be distributed to Xintelas existing shareholders through a stock dividend and listed on a suitable stock market during 2018. Since 2014, Xintela’s cancer project focusing on the aggressive brain tumor […]

Year-end Report 2017

Strategic decisions, collaboration agreements and financing Xintela took major steps forward in 2017 and there is every reason to be optimistic about the new year. Our unique stem cell technology and the decision to establish our own GMP facility for stem cell production have made us a player to reckon with in regenerative medicine. We […]